Trials / Suspended
SuspendedNCT01202630
BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
A Triple-blind, Randomized, Placebo-controlled, Multi-center Study on the Effect of BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
- Status
- Suspended
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Bio-K Plus International Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of BIO-K+ CL1285 for prevention of recurrent Clostridium difficile infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Lactobacillus acidophilus CL1285® and Lactobacillus casei | 2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days |
| DIETARY_SUPPLEMENT | Placebo | 2 capsules of placebo (no live cells), consumed once daily for 60 days |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2010-09-16
- Last updated
- 2016-01-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01202630. Inclusion in this directory is not an endorsement.